🇺🇸 FDA
Pipeline program

LGD-6972

L6972-01

Phase 1 small_molecule completed

Quick answer

LGD-6972 for Type 2 Diabetes Mellitus is a Phase 1 program (small_molecule) at LIGAND PHARMACEUTICALS INC with 2 ClinicalTrials.gov record(s).

Program details

Company
LIGAND PHARMACEUTICALS INC
Indication
Type 2 Diabetes Mellitus
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials